GO:0071300 cellular response to retinoic acid: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071300 (cellular response to retinoic acid) describes how a single cell changes its state, movement, secretion, enzyme production or gene expression after exposure to retinoic acid.
• Retinoic acid signals are transduced by nuclear retinoic acid receptors (RARA, RARB, RARG) and retinoid X receptors, which directly regulate target gene transcription.
• Cellular retinoic acid-binding protein 2 (CRABP2) binds retinoic acid, becomes rigidified and dimerizes, and delivers the ligand to nuclear receptors.
• The stimulated-by-retinoic-acid-6 (STRA6) promoter is itself retinoic acid-responsive and is regulated in response to retinol deficiency, creating a feedback loop.
• The transcriptional repressor SNAI2 impairs neuroblastoma differentiation and inhibits the cellular response to retinoic acid therapy.
• Response strength depends on cell-intrinsic and extrinsic factors, including colony size and the specific teratocarcinoma or embryonal carcinoma cell line used.
Description
GO:0071300, cellular response to retinoic acid, is a Gene Ontology biological process that captures any change in a cell's state or activity (movement, secretion, enzyme production, gene expression, etc.) caused by a retinoic acid stimulus. Retinoic acid, also called vitamin A acid, is a small lipophilic metabolite of retinol that acts as a potent differentiation, proliferation and apoptosis signal in embryonic and adult tissues. Because the response is cell-type specific and dose-dependent, it is studied in embryonal carcinoma, teratocarcinoma, neuroblastoma, synovial sarcoma and hepatocellular carcinoma models. Understanding this process is essential for developmental biology, cancer differentiation therapy and immunology, where retinoic acid is used as an adjuvant or therapeutic agent. The term is defined by the cellular outcome rather than by a single receptor, so it encompasses rapid cytoplasmic events, nuclear receptor activation and long-term transcriptional reprogramming.
cellular response to retinoic acid At A Glance
| GO ID | GO:0071300 |
|---|---|
| GO term | cellular response to retinoic acid |
| Ontology | biological_process |
| Synonym | cellular response to vitamin A acid |
| Definition | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a retinoic acid stimulus. |
| Major function | Transduces retinoic acid signals into transcriptional and phenotypic changes, including differentiation, growth arrest and apoptosis. |
| Key receptors | RARA, RARB, RARG and retinoid X receptors. |
| Key binding proteins | CRABP2 and STRA6-mediated retinol/retinoic acid handling. |
| Representative cell models | Embryonal carcinoma, teratocarcinoma, neuroblastoma, synovial sarcoma and hepatocellular carcinoma cells. |
What Is GO:0071300?
In our own words, GO:0071300 describes the set of intracellular processes triggered when a cell encounters retinoic acid. It includes ligand uptake and binding by cellular retinoic acid-binding proteins, nuclear receptor activation, changes in gene expression, and downstream alterations in cell movement, secretion, enzyme activity, proliferation or differentiation. The response is not a single linear pathway but a network whose output depends on the cell type, the concentration of retinoic acid and the presence of co-regulators such as EZH2 or SNAI2.
Why Is cellular response to retinoic acid Important in Cell Biology?
The cellular response to retinoic acid is important because it controls fundamental decisions such as whether a cell divides, differentiates or dies, and because pharmacological retinoic acid is already used in differentiation therapy for acute promyelocytic leukemia and is being tested in solid tumors and vaccine adjuvants. Defects or resistance in this response contribute to neuroblastoma aggressiveness, synovial sarcoma senescence escape and hepatocellular carcinoma progression. Studying GO:0071300 therefore connects basic retinoid biology to clinically actionable mechanisms.
• Drives differentiation of embryonal carcinoma and teratocarcinoma cells, making it a classic developmental model.
• Mediates retinoic acid-induced senescence in synovial sarcoma, which can be enhanced by EZH2 inhibition.
• Supports neuroblastoma differentiation, and its blockade by SNAI2 causes therapy resistance.
• Modulates hepatocellular carcinoma responsiveness to all-trans retinoic acid through RARG expression.
• Regulates STRA6 promoter activity in response to retinol deficiency, linking vitamin A status to gene expression.
• Involves CRABP2 structural changes that are required for efficient nuclear delivery of retinoic acid.
• Enhances humoral, cellular and gastrointestinal mucosal immunity in nanoparticle-based vaccine formulations.
• Provides a paradigm for ligand-dependent nuclear receptor signaling and transcriptional control.
• Is a target for combination therapies that sensitize resistant tumors to retinoids.
• Can be studied with CRISPR knockout, point mutation and knock-in models to dissect causal genes.
What Happens During cellular response to retinoic acid?
Retinoic acid uptake and intracellular binding
In simple terms: First, the cell takes up retinoic acid and a carrier protein grabs it.
Retinoic acid enters cells and is bound by cellular retinoic acid-binding protein 2 (CRABP2). Binding causes CRABP2 rigidification and dimerization, a structural change that is thought to facilitate nuclear delivery of the ligand. The STRA6 promoter can also respond to retinoic acid and to retinol deficiency, providing a feedback mechanism that adjusts retinoid handling.
Nuclear receptor activation and transcriptional reprogramming
In simple terms: Inside the nucleus, retinoic acid switches on receptors that turn genes on or off.
Retinoic acid binds nuclear retinoic acid receptors (RARA, RARB, RARG), which heterodimerize with retinoid X receptors and regulate target gene transcription. In hepatocellular carcinoma, upregulation of RARG expression enhances the cellular response to all-trans retinoic acid, showing that receptor abundance is a key determinant of the response.
Epigenetic and repressor control of the response
In simple terms: Other proteins can put brakes on the response, and removing those brakes makes cells more sensitive.
EZH2 inhibition sensitizes synovial sarcoma cells to retinoic acid-driven senescence, indicating that polycomb repressive complexes restrain the cellular response to retinoic acid. The transcriptional repressor SNAI2 impairs neuroblastoma differentiation and inhibits the response to retinoic acid therapy, providing another layer of negative regulation.
Cell-context determinants of response strength
In simple terms: Not every cell responds the same way; the cell type and even colony size matter.
Two teratocarcinoma cell lines show different responses to retinoic acid, demonstrating cell-intrinsic differences in the response machinery. In embryonal carcinoma cells, the response to retinoic acid depends on colony size, showing that cell density and microenvironment also influence the outcome.
Downstream phenotypic outputs
In simple terms: The final result can be differentiation, growth arrest, senescence or immune activation.
Depending on context, the cellular response to retinoic acid leads to differentiation (neuroblastoma, embryonal carcinoma), senescence (synovial sarcoma), altered proliferation (hepatocellular carcinoma) or enhanced humoral, cellular and gastrointestinal mucosal immunity in nanoparticle vaccine settings.
Key Genes Involved in GO:0071300 cellular response to retinoic acid
The following genes and proteins are experimentally implicated in the cellular response to retinoic acid (GO:0071300) in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RARA | Retinoic acid receptor alpha; ligand-activated transcription factor | Core receptor mediating transcriptional response to retinoic acid |
| RARB | Retinoic acid receptor beta; transcription factor | Contributes to retinoic acid-dependent gene regulation |
| RARG | Retinoic acid receptor gamma; transcription factor | Upregulation enhances ATRA response in hepatocellular carcinoma |
| CRABP2 | Cellular retinoic acid-binding protein 2; intracellular transport | Binds retinoic acid and undergoes rigidification and dimerization |
| STRA6 | Stimulated by retinoic acid 6; membrane receptor for retinol uptake | Retinoic acid-responsive promoter regulated by retinol deficiency |
| SNAI2 | Transcriptional repressor | Impairs neuroblastoma differentiation and inhibits retinoic acid response |
| EZH2 | Histone methyltransferase; polycomb repressive complex 2 subunit | Its inhibition sensitizes synovial sarcoma to retinoic acid-driven senescence |
| RXRA | Retinoid X receptor alpha; heterodimer partner | Forms heterodimers with RARs to mediate retinoic acid signaling |
| RXRB | Retinoid X receptor beta; heterodimer partner | Part of the nuclear receptor complex for retinoic acid response |
| RXRG | Retinoid X receptor gamma; heterodimer partner | Contributes to retinoid receptor heterodimer diversity |
| TP53 | Tumor suppressor; apoptosis and senescence regulator | Downstream effector of retinoic acid-induced growth arrest |
| CDKN1A | Cyclin-dependent kinase inhibitor 1A (p21); cell cycle arrest | Mediates retinoic acid-induced proliferation arrest |
| MYCN | MYCN proto-oncogene; transcription factor | Context for neuroblastoma differentiation and retinoic acid resistance |
| ALDH1A1 | Aldehyde dehydrogenase 1 family member A1; retinoic acid synthesis | Contributes to local retinoic acid production |
| ALDH1A2 | Aldehyde dehydrogenase 1 family member A2; retinoic acid synthesis | Enzyme for retinoic acid biosynthesis |
| CYP26A1 | Cytochrome P450 family 26 subfamily A member 1; retinoic acid degradation | Limits retinoic acid levels and shapes the response |
| CYP26B1 | Cytochrome P450 family 26 subfamily B member 1; retinoic acid degradation | Modulates retinoic acid availability |
| RBP1 | Retinol binding protein 1; retinol transport | Supports intracellular retinoid handling |
How Is cellular response to retinoic acid Regulated?
The cellular response to retinoic acid is regulated at multiple levels. Receptor abundance, exemplified by RARG upregulation in hepatocellular carcinoma, determines sensitivity to all-trans retinoic acid. Epigenetic repression by EZH2 restrains retinoic acid-driven senescence in synovial sarcoma, and EZH2 inhibition releases this brake. The transcriptional repressor SNAI2 impairs neuroblastoma differentiation and inhibits the response to retinoic acid therapy. CRABP2 binding and structural changes regulate ligand delivery to the nucleus, while the retinoic acid-responsive STRA6 promoter adjusts retinoid handling under retinol deficiency. Cell density and colony size further modulate the response in embryonal carcinoma cells.
cellular response to retinoic acid and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EZH2 | Synovial sarcoma senescence escape | EZH2 knockout or point-mutation synovial sarcoma cells treated with retinoic acid |
| SNAI2 | Neuroblastoma differentiation block and retinoic acid resistance | SNAI2 knockout or overexpression neuroblastoma cells |
| RARG | Hepatocellular carcinoma ATRA response | RARG knock-in or knockout hepatocellular carcinoma cells |
| STRA6 | Retinol deficiency and retinoid homeostasis | STRA6 promoter reporter knock-in cells under retinol restriction |
| CRABP2 | Retinoic acid intracellular transport | CRABP2 point-mutation or knockout cells for ligand delivery assays |
Cancer differentiation therapy and resistance
Retinoic acid is used to force differentiation or senescence in several cancers. In synovial sarcoma, EZH2 inhibition sensitizes cells to retinoic acid-driven senescence, suggesting a combination strategy. In neuroblastoma, SNAI2 impairs differentiation and inhibits the response to retinoic acid therapy, identifying a resistance mechanism. In hepatocellular carcinoma, GSK-126 enhances the all-trans retinoic acid response by upregulating RARG expression.
Developmental and teratocarcinoma models
Embryonal carcinoma and teratocarcinoma cell lines are classic models for retinoic acid-induced differentiation. Different teratocarcinoma cell lines respond differently to retinoic acid, and the response of embryonal carcinoma cells depends on colony size. These findings show that the cellular response to retinoic acid is context-dependent and relevant to developmental biology.
Immunology and vaccine adjuvants
Retinoic acid combined with resveratrol in quaternized chitosan-coated PLGA nanoparticles enhances humoral immunity, cellular immunity and gastrointestinal mucosal immunity, demonstrating that the cellular response to retinoic acid can be harnessed for vaccine design.
Vitamin A deficiency and retinoid homeostasis
An alternative retinoic acid-responsive STRA6 promoter is regulated in response to retinol deficiency, linking the cellular response to retinoic acid to vitamin A status and retinoid homeostasis.
From cellular response to retinoic acid-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is RARG required for the cellular response to retinoic acid? | RARG knockout hepatocellular carcinoma cells |
| Does EZH2 loss sensitize cells to retinoic acid? | EZH2 knockout synovial sarcoma cells |
| Does SNAI2 block neuroblastoma differentiation? | SNAI2 overexpression or knockout neuroblastoma cells |
| How does CRABP2 dimerization affect ligand delivery? | CRABP2 point-mutation knock-in cells |
| Is the STRA6 promoter retinoic acid-responsive? | STRA6 promoter reporter knock-in cells |
| Does colony size change the response? | Embryonal carcinoma colony-size-controlled cultures |
How to Study the cellular response to retinoic acid Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptional changes after retinoic acid | Identify retinoic acid-responsive genes and pathways |
| ChIP-seq | Receptor occupancy on chromatin | Map RAR/RXR binding sites after retinoic acid |
| Western blot | Protein expression and modification | Measure RARG, SNAI2, EZH2 or CRABP2 levels |
| Senescence assay | Senescence-associated beta-galactosidase activity | Detect retinoic acid-induced senescence in synovial sarcoma |
| Differentiation markers | Neurite outgrowth or lineage markers | Assess neuroblastoma differentiation after retinoic acid |
| Colony formation assay | Clonogenic growth and colony size | Test density-dependent retinoic acid response |
| Immunization and titer assays | Humoral and mucosal immune responses | Evaluate retinoic acid-containing nanoparticle vaccines |
| Reporter assay | Promoter activity | Test STRA6 promoter response to retinoic acid and retinol deficiency |
Transcriptional profiling of the retinoic acid response
RNA-seq before and after retinoic acid treatment identifies genes whose expression changes as part of GO:0071300. This approach has been used to show RARG upregulation in hepatocellular carcinoma and to define retinoic acid-responsive promoters such as STRA6.
Protein-ligand interaction and structural assays
Biochemical and structural methods demonstrate that retinoic acid binding leads to CRABP2 rigidification and dimerization, providing mechanistic insight into ligand handling.
Phenotypic differentiation and senescence assays
Differentiation markers, senescence-associated beta-galactosidase and proliferation assays are used to measure the cellular response to retinoic acid in neuroblastoma, synovial sarcoma and teratocarcinoma models.
Immunological and mucosal immunity readouts
Antibody titers, cellular immunity assays and gastrointestinal mucosal immunity measurements can quantify the retinoic acid component of nanoparticle vaccine formulations.
How CRISPR Can Be Used to Study GO:0071300 cellular response to retinoic acid
Knockout
CRISPR knockout of RARG, EZH2 or SNAI2 can test whether these genes are required for the cellular response to retinoic acid. For example, EZH2 knockout is expected to sensitize synovial sarcoma cells to retinoic acid-driven senescence, and SNAI2 knockout may restore neuroblastoma differentiation.
Point Mutation
Point mutations in CRABP2 can be introduced to test which residues are required for retinoic acid binding, rigidification and dimerization. Point mutations in nuclear receptor ligand-binding domains can dissect receptor-specific contributions to GO:0071300.
Knock-in
Knock-in of a reporter or tag at the STRA6 promoter allows direct measurement of retinoic acid-responsive transcription under retinol deficiency. Tagged knock-in of RARG or CRABP2 enables localization and interaction studies in live cells.
Overexpression
Overexpression of SNAI2 can reproduce the differentiation block and retinoic acid resistance seen in neuroblastoma. Overexpression of RARG can enhance the all-trans retinoic acid response in hepatocellular carcinoma cells.
How EDITGENE Supports cellular response to retinoic acid Research
Researchers studying cellular response to retinoic acid-related genes often need to determine whether a candidate gene is causally involved in ligand sensing, transcriptional reprogramming or phenotypic output. EDITGENE provides CRISPR-engineered cell models that make these causal tests reproducible and publication-ready.
Contact EDITGENE today to design your custom CRISPR model for cellular response to retinoic acid research.
Frequently Asked Questions About cellular response to retinoic acid
What is GO:0071300 cellular response to retinoic acid?
GO:0071300 is a Gene Ontology biological process describing any change in a cell's state or activity, such as movement, secretion, enzyme production or gene expression, caused by a retinoic acid stimulus.
What genes are involved in the cellular response to retinoic acid?
Key genes include RARA, RARB, RARG, RXRA, RXRB, RXRG, CRABP2, STRA6, SNAI2 and EZH2, as shown in the cited literature.
How does retinoic acid change gene expression?
Retinoic acid binds nuclear retinoic acid receptors such as RARG, which heterodimerize with retinoid X receptors and regulate target gene transcription.
What is the role of CRABP2 in retinoic acid signaling?
CRABP2 binds retinoic acid and undergoes rigidification and dimerization, which is thought to facilitate nuclear delivery of the ligand.
How is STRA6 related to retinoic acid?
STRA6 has a retinoic acid-responsive promoter that is regulated in response to retinol deficiency, linking retinoid status to gene expression.
Why do some cancer cells resist retinoic acid therapy?
Resistance can arise from transcriptional repressors such as SNAI2, which impairs neuroblastoma differentiation and inhibits the response to retinoic acid therapy.
Can EZH2 inhibition improve retinoic acid response?
Yes, EZH2 inhibition sensitizes synovial sarcoma cells to retinoic acid-driven senescence.
Does RARG expression affect ATRA response in liver cancer?
Upregulation of RARG expression enhances the all-trans retinoic acid response in hepatocellular carcinoma.
How is the cellular response to retinoic acid studied experimentally?
Common methods include RNA-seq, ChIP-seq, western blot, senescence assays, differentiation markers, colony formation assays and reporter assays.
Can CRISPR be used to study GO:0071300?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models can test causal roles of RARG, EZH2, SNAI2, CRABP2 and STRA6 in the retinoic acid response.
Conclusion
GO:0071300 cellular response to retinoic acid is a central biological process that converts a small lipid signal into transcriptional and phenotypic changes. The cited literature shows that nuclear receptors, binding proteins, epigenetic regulators and transcriptional repressors together determine whether a cell differentiates, senesces, proliferates or resists therapy. Because the response is context-dependent, CRISPR-engineered cell models are valuable for dissecting causal mechanisms and for developing combination strategies that sensitize resistant cancers to retinoids.
References
- 1. Yang D et al.. 2025. Quaternized chitosan-coated PLGA nanoparticles co-deliver resveratrol and all-trans retinoic acid to enhance humoral immunity, cellular immunity and gastrointestinal mucosal immunity.. Colloids Surf B Biointerfaces 256(Pt 1):114994 PMID: 40774228
- 2. Mushtaq M et al.. 2024. EZH2 inhibition sensitizes retinoic acid-driven senescence in synovial sarcoma.. Cell Death Dis 15(11):836 PMID: 39550391
- 3. Laursen KB et al.. 2015. An alternative retinoic acid-responsive Stra6 promoter regulated in response to retinol deficiency.. J Biol Chem 290(7):4356-66 PMID: 25544292
- 4. Vrenken KS et al.. 2020. The transcriptional repressor SNAI2 impairs neuroblastoma differentiation and inhibits response to retinoic acid therapy.. Biochim Biophys Acta Mol Basis Dis 1866(3):165644 PMID: 31862304
- 5. Lixa C et al.. 2019. Retinoic Acid Binding Leads to CRABP2 Rigidification and Dimerization.. Biochemistry 58(41):4183-4194 PMID: 31566355
- 6. Liu Z et al.. 2024. GSK-126 Enhances All-Trans-Retinoic Acid (ATRA) Response in Hepatocellular Carcinoma (HCC) by Upregulating RARG Expression.. Discov Med 36(184):1041-1053 PMID: 38798263
- 7. Wan YJ et al.. 1995. Different response to retinoic acid of two teratocarcinoma cell lines.. Exp Cell Res 219(2):392-8 PMID: 7543852
- 8. Koopman P et al.. 1986. The response of embryonal carcinoma cells to retinoic acid depends on colony size.. Differentiation 31(1):55-60 PMID: 3732659
